Pages that link to "Q34458323"

The following pages link to Increased expression of EZH2, a polycomb group protein, in bladder carcinoma (Q34458323):

Displaying 41 items.

• The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer (Q28253014) (← links)
• Polycomb silencers control cell fate, development and cancer (Q29619697) (← links)
• Expression of polycomb group protein EZH2 in nevi and melanoma (Q33291217) (← links)
• Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo. (Q34786445) (← links)
• Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer (Q34964303) (← links)
• Chromatin Memory in the Development of Human Cancers (Q34979975) (← links)
• Impact of EZH2 polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic features (Q35137483) (← links)
• Connections between epigenetic gene silencing and human disease (Q35843804) (← links)
• Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression (Q35849140) (← links)
• Quantitative Assessment of the Polymorphisms in the HOTAIR lncRNA and Cancer Risk: A Meta-Analysis of 8 Case-Control Studies (Q35969025) (← links)
• Cancer genetics of epigenetic genes (Q36871595) (← links)
• Epigenetic regulator polycomb group protein complexes control cell fate and cancer (Q37142189) (← links)
• Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer (Q37629613) (← links)
• Epigenetic factors in cancer development: polycomb group proteins (Q37822735) (← links)
• Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2 (Q37822876) (← links)
• EZH2, an epigenetic driver of prostate cancer (Q38103472) (← links)
• Epigenetic modification in gliomas: role of the histone methyltransferase EZH2. (Q38232172) (← links)
• Histone modifications: Targeting head and neck cancer stem cells (Q38271597) (← links)
• Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder (Q40095050) (← links)
• Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. (Q40273857) (← links)
• Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters (Q41336798) (← links)
• Polycomb Repressor Complex 2 in Genomic Instability and Cancer (Q41573279) (← links)
• Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy (Q41918438) (← links)
• SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer (Q42314701) (← links)
• Spatiotemporal expression of Ezh2 in the developing mouse cochlear sensory epithelium (Q42496908) (← links)
• Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder (Q45246975) (← links)
• EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index (Q48117546) (← links)
• Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer (Q48200477) (← links)
• Targeting the epigenome for treatment of cancer. (Q53201323) (← links)
• High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not (Q53270368) (← links)
• Effects of four single nucleotide polymorphisms of EZH2 on cancer risk: a systematic review and meta-analysis. (Q53273169) (← links)
• NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. (Q53538138) (← links)
• Transcriptional deregulation underlying the pathogenesis of small cell lung cancer. (Q55011897) (← links)
• [Advances on Driver Mutations of Small Cell Lung Cancer]. (Q55464542) (← links)
• Emerging EZH2 Inhibitors and Their Application in Lymphoma (Q57136305) (← links)
• Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma (Q57141720) (← links)
• Epigenetic Mechanisms in Cancer Formation and Progression (Q57570317) (← links)
• Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker (Q84025680) (← links)
• Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma (Q87134498) (← links)
• MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis (Q88030471) (← links)
• MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity (Q92838509) (← links)